Within 12 months of starting tafamidis, 9% of patients had events, and up to one-third exhibited markers of disease progression. Worsening in NYHA functional class, NAC/Mondor stage, NT-proBNP, eGFR, and ODI were associated with adverse prognosis.
Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis
Faro, DeniseInvestigation
;Monte, Ines PaolaData Curation
;
2025-01-01
Abstract
Within 12 months of starting tafamidis, 9% of patients had events, and up to one-third exhibited markers of disease progression. Worsening in NYHA functional class, NAC/Mondor stage, NT-proBNP, eGFR, and ODI were associated with adverse prognosis.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2025_JACC.pdf
accesso aperto
Descrizione: articolo in rivista
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
3.56 MB
Formato
Adobe PDF
|
3.56 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
